Please assess the completion status of the following clinical trial:

Trial Title: Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who fulfil the diagnostic criteria of HLH.~Exclusion Criteria:~* Prior cytotoxic or cyclosporin treatment for HLH.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Etoposide, Dexamethasone, Cyclosporin A plus IT MTX & Steroids (Type: EXPERIMENTAL): As compared to the HLH-94 treatment, the main changes are that~1. Cyclosporin A is administered from day 1 and~2. Intrathecal steroids are added to the intrathecal methotrexate.~Drugs, dosage, frequency and duration are described in the paragraph Interventions below.

Based on this trial design, predict the completion outcome and termination type (if applicable).